← All drugs Report issue

bms-823778

Small moleculeexperimental

Clinical trial activity

5 trials · 1 clinical orgs · 0 marketing orgs

Phase 1

1

Phase 2

4

Phase 3

0

Phase 4

0

Earliest trial started Jun 1, 2010 (NCT01112423)

Timeline

2010s

Jan 1, 2010
Earliest Phase 2 Sponsor(trial)
Jan 1, 2012
Earliest Phase 1 Sponsor(trial)

Indications

Studied for

Mechanism of action

11-beta-hydroxysteroid dehydrogenaseANTAGONIST
11-beta-hydroxysteroid dehydrogenase antagonist
- Corticosteroid 11-beta-dehydrogenase isozyme 2 (HSD11B2) ↗
- Corticosteroid 11-beta-dehydrogenase isozyme 1 (HSD11B1) ↗
- 11-beta-hydroxysteroid dehydrogenase 1
- 11-beta-hydroxysteroid dehydrogenase 2
11-beta-hydroxysteroid dehydrogenase 1INHIBITOR
11-beta-hydroxysteroid dehydrogenase 1 inhibitor
- Corticosteroid 11-beta-dehydrogenase isozyme 1 (HSD11B1) ↗

Chemistry & pharmacology

Loading structure…

SMILES

CC(C)(O)c1cccn2c(C3(c4ccc(Cl)cc4)CC3)nnc12.Cl

Mol. weight: 364.28 g/mol
Lipinski Ro5: Pass
Rule of 3: No
Chirality: Achiral Molecule
Inorganic: No
Polymer: No

Oral

No

Parenteral

No

Topical

No

Sources

ChEMBLCHEMBL4301600 ↗
ChEMBLCHEMBL4297457 ↗

Also known as

bms-823778
bms-823778

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT01666704	Phase 2	Apr 1, 2014	Bristol-Myers Squibb
NCT01602367	Phase 2	Jul 1, 2012	Bristol-Myers Squibb
NCT01515202	Phase 1	Mar 1, 2012	Bristol-Myers Squibb
NCT01111955	Phase 2	Jul 1, 2010	Bristol-Myers Squibb
NCT01112423	Phase 2	Jun 1, 2010	Bristol-Myers Squibb

Showing 5 of 5 trials

Page 1 / 1

Organizations

Research & Development (1)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Bristol-Myers Squibb	For profit	5	5	2	2010

1 organizations

Page 1 / 1